Castleark Management LLC bought a new stake in shares of Twist Bioscience Corp (NASDAQ:TWST) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 127,744 shares of the company’s stock, valued at approximately $3,706,000. Castleark Management LLC owned 0.39% of Twist Bioscience at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its holdings in Twist Bioscience by 90.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,997,857 shares of the company’s stock valued at $56,220,000 after acquiring an additional 947,399 shares during the period. Emerald Advisers LLC raised its position in Twist Bioscience by 146.5% during the 2nd quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after purchasing an additional 344,463 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its position in Twist Bioscience by 156.0% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after purchasing an additional 319,373 shares during the last quarter. ARK Investment Management LLC bought a new position in Twist Bioscience during the 2nd quarter valued at approximately $6,202,000. Finally, Asymmetry Capital Management L.P. raised its position in shares of Twist Bioscience by 624.3% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 171,903 shares of the company’s stock worth $4,987,000 after acquiring an additional 148,170 shares in the last quarter. Institutional investors own 42.69% of the company’s stock.
In other news, CTO Bill Peck sold 20,447 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $28.43, for a total transaction of $581,308.21. Following the sale, the chief technology officer now directly owns 711,839 shares of the company’s stock, valued at $20,237,582.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Patrick Weiss sold 14,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $27.66, for a total transaction of $407,376.48. Following the sale, the senior vice president now directly owns 108,969 shares in the company, valued at $3,014,082.54. The disclosure for this sale can be found here. Insiders have sold 139,686 shares of company stock valued at $4,080,780 in the last 90 days. Company insiders own 29.40% of the company’s stock.
TWST stock opened at $23.72 on Friday. Twist Bioscience Corp has a 1 year low of $12.38 and a 1 year high of $35.95. The stock’s fifty day moving average price is $28.53 and its 200-day moving average price is $27.21. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.96 and a current ratio of 7.18.
Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, August 1st. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.83) by ($0.09). Twist Bioscience had a negative return on equity of 168.45% and a negative net margin of 204.63%. The firm had revenue of $13.60 million during the quarter, compared to the consensus estimate of $12.51 million. On average, sell-side analysts expect that Twist Bioscience Corp will post -3.8 EPS for the current year.
TWST has been the subject of several research reports. ValuEngine raised Twist Bioscience from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Evercore ISI began coverage on Twist Bioscience in a research note on Friday, May 31st. They issued an “outperform” rating and a $26.66 price target on the stock. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $26.55.
Twist Bioscience Company Profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
See Also: Why do companies engage in swaps?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.